OptiNose (NASDAQ:OPTN) stock surges 61% as Paratek Pharmaceuticals agrees to a $330M acquisition. Read mroe here.
Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient marketAcquisition advances Paratek’s ...
A stuffy nose can make it incredibly difficult to get a good night’s sleep. When congestion blocks your nasal passages, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback